In recent years, the enthusiasm for mergers and acquisitions of listed biopharmaceutical companies has been high
.
According to the data, among the M&A statistics in the past three years, the biopharmaceutical industry is second only to machinery and equipment.
The ratio is 8.
46%
.
Since 2022, the enthusiasm for mergers and acquisitions of biopharmaceutical companies has remained high
.
Recently, mergers and acquisitions in the A-share biopharmaceutical field have been very active
.
Data show that since August, 9 A-share pharmaceutical and biological institutions have launched mergers and acquisitions within 10 days, involving a total amount of more than 2.
7 billion yuan
.
These companies include: Huadong Medicine acquired 60% equity of Huaren Technology; Dorui Medicine planned to acquire 40% equity of Bozhou Tianji held by Hubei Tianji; China Resources Shuanghe planned to acquire 50.
11% equity of Shenzhou Biotechnology.
.
.
Among the recent mergers and acquisitions, the one involving a relatively large amount was on August 7, when a pharmaceutical company announced that it planned to purchase part of the equity of a pharmaceutical company in Guangzhou for about 1.
003 billion yuan in cash
.
After the transaction is completed, the company will hold more than 90% of the shares of the acquired target
.
Secondly, China Resources Pharmaceutical has carried out two acquisitions with a total amount of more than 800 million yuan
.
China Resources Pharmaceutical announced on August 4 that its subsidiary China Resources Shuanghe Pharmaceutical Co.
, Ltd.
acquired a 50.
11% stake in Shenzhou Biotechnology for 501 million yuan, and increased its 31.
25% stake in Tiandong Pharmaceutical for 307 million yuan.
70% shares of Tiandong Pharmaceutical
.
Industry analysts believe that mergers and acquisitions in the biopharmaceutical field have become an industry trend.
On the one hand, the biopharmaceutical industry itself is a business model that focuses on R&D and technology; on the other hand, the biopharmaceutical industry develops and advances rapidly in technology
.
At present, from an overall point of view, most biopharmaceutical companies are mainly acquired for the purpose of supplementing the company's technology and customer base accumulation in the innovation sector, improving the industrial layout, and enhancing the company's profitability
.
It is worth mentioning that in addition to accelerating the acquisition of domestic assets, many domestic pharmaceutical companies have fallen in love with the acquisition of overseas companies since the beginning of this year, and accelerated their internationalization by acquiring overseas companies, such as Qiming Medical, Kanglong Chemical, and Sihuan Pharmaceutical Subsidiaries.
Company, Asymchem, Woby Medical, China Biopharmaceutical,
etc.
In this regard, the industry generally believes that mergers and acquisitions in the field of medicine and biology have become a major trend
.
Under the influence of China's aging population, coupled with the continuous advancement of medical insurance negotiations and centralized procurement by the state, the state encourages new drug R&D and innovation policies to continuously drive the continuous innovation and transformation of pharmaceutical companies, and promote the merger and reorganization of drug production and distribution companies.
The speed of financing and mergers and acquisitions will continue to accelerate
.
Affected by this, mergers and acquisitions in the biopharmaceutical industry are also expected to accelerate in the second half of the year
.
Analysts pointed out that in the second half of the year, M&A opportunities may mainly appear in new tracks such as high-end medical equipment, medical aesthetics, ophthalmic consumer products, vaccines, specialist medical care and Internet medical care.
Equal inclination
.
However, at the same time, for enterprises, in the future, it is also necessary to pay more attention to avoid duplication of construction and disorderly expansion, and avoid stepping on thunder
.
